The inhibitory effects of camptothecin (CPT) and its derivatives on the substrate uptakes mediated by human solute carrier transporters (SLCs)

References

• Burckhardt G. (2012). Drug transport by organic anion transporters (OATs). Pharmacol Ther 136:106–30
   PubMed Web of Science ®Google Scholar
• Cao Z. (1999). Methods of preparing and purifying 9-nitro-20-camptothecin. US Patent 5922877 A
   Google Scholar
• Cao Z, Harris N, Kozielski A, et al. (1998). Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity. J Med Chem 41:31–7
   PubMed Web of Science ®Google Scholar
• Cao Z, Pantazis P, Mendoza J, et al. (2000). Structure–activity relationship of alkyl camptothecin esters. Ann NY Acad Sci 922:122–35
   PubMed Web of Science ®Google Scholar
• Chan T, Li Z, Zheng J, et al. (2013). Inhibitory effects of apigenin and kaempferol on the essential solute carrier transporters. World J Pharmacol 2:115–21
   Google Scholar
• DeGorter MK, Xia CQ, Yang JJ, Kim RB. (2012). Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol 52:249–73
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG. (2002). Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641–61
   PubMed Web of Science ®Google Scholar
• Gottlieb JA, Luce JK. (1972). Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56:103–5
   PubMedGoogle Scholar
• Grundemann D, Harlfinger S, Golz S, et al. (2005). Discovery of the ergothioneine transporter. Proc Natl Acad Sci USA 102:5256–61
   PubMed Web of Science ®Google Scholar
• Gupta E, Luo F, Lallo A, et al. (2000). The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s). Anticancer Res 20:1013–6
   PubMed Web of Science ®Google Scholar
• Gupta S, Wulf G, Henjakovic M, et al. (2012). Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel. J Pharmacol Exp Ther 341:16–23
   PubMed Web of Science ®Google Scholar
• Harris RC, Zhang MZ. (2012). Dopamine, the kidney, and hypertension. Curr Hypertens Rep 14:138–43
   PubMed Web of Science ®Google Scholar
• Hinz HR, Harris NJ, Natelson EA, Giovanella BC. (1994). Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice. Cancer Res 54:3096–100
   PubMed Web of Science ®Google Scholar
• Huang SH, Chao Y, Wu YY, et al. (2011). Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer. Tumori 97:243–7
   PubMed Web of Science ®Google Scholar
• Johnston RA, Rawling T, Chan T, et al. (2014). Selective inhibition of human solute carrier transporters by multikinase inhibitors. Drug Metab Dispos 42:1851–7
   PubMed Web of Science ®Google Scholar
• Klaassen CD, Aleksunes LM. (2010). Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 62:1–96
   PubMed Web of Science ®Google Scholar
• Li Z, Cheung FS, Zheng J, et al. (2014). Interaction of the bioactive flavonol, icariin, with the essential human solute carrier transporters. J Biochem Mol Toxicol 28:91–7
   PubMed Web of Science ®Google Scholar
• Li S, Jiang W, Zhang L, et al. (2001). A comparison of clinical pharmacokinetic and pharmacodynamic of different administration schedules of intravenous 10-hydroxycamptothecin. Chin J Clin Pharmacol 17:427–30
   Google Scholar
• Li M, Jin W, Jiang C, et al. (2009). 7-Cycloalkylcamptothecin derivatives: preparation and biological evaluation. Bioorg Med Chem Lett 19:4107–9
   PubMed Web of Science ®Google Scholar
• Liehr JG, Harris NJ, Mendoza J, et al. (2000). Pharmacology of camptothecin esters. Ann NY Acad Sci 922:216–23
   PubMed Web of Science ®Google Scholar
• Lin LC, Wang MN, Tsai TH. (2008). Food–drug interaction of (−)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38. Chem Biol Interact 174:177–82
   PubMed Web of Science ®Google Scholar
• Liu X, Wang Y, Vardeman D, et al. (2008). Development and validation of a reverse-phase HPLC with fluorescence detector method for simultaneous determination of CZ48 and its active metabolite camptothecin in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 867:84–9
   PubMed Web of Science ®Google Scholar
• Masuda N, Fukuoka M, Kudoh S, et al. (1994). Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 12:90–6
   PubMed Web of Science ®Google Scholar
• Matsumoto S-I, Yoshida K, Ishiguro N, et al. (2007). Involvement of rat and human organic anion transporter 3 in the renal tubular secretion of topotecan [(S)-9-dimethylaminomethyl-10-hydroxy-camptothecin hydrochloride]. J Pharmacol Exp Ther 322:1246–52
   PubMed Web of Science ®Google Scholar
• Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. (1972). Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95–101
   PubMedGoogle Scholar
• Muggia FM, Creaven PJ, Hansen HH, et al. (1972). Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56:515–21
   PubMedGoogle Scholar
• Nishimura M, Naito S. (2005). Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 20:452–77
   PubMedGoogle Scholar
• Nishimura M, Naito S. (2008). Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. Drug Metab Pharmacokinet 23:22–44
   PubMed Web of Science ®Google Scholar
• Nozawa T, Minami H, Sugiura S, et al. (2005). Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33:434–9
   PubMed Web of Science ®Google Scholar
• Ohashi R, Tamai I, Yabuuchi H, et al. (1999). Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther 291:778–84
   PubMed Web of Science ®Google Scholar
• O’Leary J, Muggia FM. (1998). Camptothecins: a review of their development and schedules of administration. Eur J Cancer 34:1500–8
   PubMed Web of Science ®Google Scholar
• Patel H, Stoller R, Auber M, et al. (2006). Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy. Invest New Drugs 24:359–63
   PubMed Web of Science ®Google Scholar
• Pitot HC, Adjei AA, Reid JM, et al. (2006). A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Cancer Chemother Pharmacol 58:165–72
   PubMed Web of Science ®Google Scholar
• Pizzolato JF, Saltz LB. (2003). The camptothecins. Lancet 361:2235–42
   PubMed Web of Science ®Google Scholar
• Potmesil M. (1994). Camptothecins: from bench research to hospital wards. Cancer Res 54:1431–9
   PubMed Web of Science ®Google Scholar
• Rabba AK, Si L, Xue K, et al. (2011). In situ intestinal perfusion of irinotecan: application to P-gp mediated drug interaction and introduction of an improved HPLC assay. J Pharm Pharm Sci 14:138–47
   PubMed Web of Science ®Google Scholar
• Roth M, Obaidat A, Hagenbuch B. (2012). OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 165:1260–87
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Grochow LB, Ettinger DS, et al. (1994). Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427–36
   PubMed Web of Science ®Google Scholar
• Segel IH. (1975) Enzyme kinetics: behaviour and analysis of rapid equilibrium and steady-state enzyme systems. New York: John Wiley & Sons
   Google Scholar
• Shnitsar V, Eckardt R, Gupta S, et al. (2009). Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res 69:1494–501
   PubMed Web of Science ®Google Scholar
• Sugiyama Y, Kato Y, Chu X. (1998). Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol 42:S44–9
   PubMed Web of Science ®Google Scholar
• Toh DS, Cheung FS, Murray M, et al. (2013). Functional analysis of novel variants in the organic cation/ergothioneine transporter 1 identified in Singapore populations. Mol Pharm 10:2509–16
   PubMed Web of Science ®Google Scholar
• Toh DS, Murray M, Pern Tan K, et al. (2011). Functional analysis of pharmacogenetic variants of human organic cation/carnitine transporter 2 (hOCTN2) identified in Singaporean populations. Biochem Pharmacol 82:1692–9
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, dos Santos Pereira JN, Meineke I, et al. (2013). Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol 86:666–78
   PubMed Web of Science ®Google Scholar
• Ueo H, Motohashi H, Katsura T, Inui K. (2005). Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol 70:1104–13
   PubMed Web of Science ®Google Scholar
• Wall ME, Wani MC, Cook CE, et al. (1966). Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888–90
   Web of Science ®Google Scholar
• Wani MC, Nicholas AW, Manikumar G, Wall ME. (1987). Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure–activity correlations. J Med Chem 30:1774–9
   PubMed Web of Science ®Google Scholar
• Wani MC, Ronman PE, Lindley JT, Wall ME. (1980). Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J Med Chem 23:554–60
   PubMed Web of Science ®Google Scholar
• Wani MC, Wall ME. (1969). Plant antitumor agents. II. The structure of two new alkaloids from Camptotheca acuminata. J Org Chem 34:1364–7
   Web of Science ®Google Scholar
• Weiss GJ, Chao J, Neidhart JD, et al. (2013). First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs 31:986–1000
   PubMed Web of Science ®Google Scholar
• Xu F, Li Z, Zheng J, et al. (2013). The inhibitory effects of the bioactive components isolated from Scutellaria baicalensis on the cellular uptake mediated by the essential solute carrier transporters. J Pharm Sci 102:4205–11
   PubMed Web of Science ®Google Scholar
• Zhang MZ, Harris RC. (2015). Antihypertensive mechanisms of intra-renal dopamine. Curr Opin Nephrol Hypertens 24:117–22
   PubMed Web of Science ®Google Scholar
• Zhou F, You G. (2007). Molecular insights into the structure–function relationship of organic anion transporters OATs. Pharm Res 24:28–36
   PubMed Web of Science ®Google Scholar
• Zhou F, Zhu L, Cui PH, et al. (2010). Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4). Br J Pharmacol 159:419–27
   PubMed Web of Science ®Google Scholar